physIQ announced that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the company’s Medical Advisory Board. In this role, Dr. Luke will provide expert medical counsel for physIQ’s ongoing development of solutions to aide in oncology treatments, including physIQ’s development of digital biomarkers for inflammation.
“Dr. Luke brings extensive immuno-oncology expertise to physIQ that will provide immeasurable insight into our work on inflammation and oncology treatments,” said Steve Steinhubl, MD, physIQ’s Chief Medical Officer. “As a practicing physician and researcher, he brings the vision, experience, and empathy that we embrace at physIQ.”
One of Dr. Luke’s first projects with physIQ is to serve as principal investigator on a clinical study designed to show how physIQ’s Inflammatory Multivariate Change Index (iMCI) can make CAR-T, a ground-breaking oncology treatment, safer and more accessible by enabling real-time in-home safety monitoring post CAR-T dosing. Dr. Luke is the Director of the Immunotherapy and Drug Development Center at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and Associate Professor at the University of Pittsburgh. He focuses on translational therapeutic advances in immuno-oncology, early phase drug development for advanced solid tumors and the management of patients with cutaneous malignancies.
In melanoma, Dr. Luke has designed and led two practice changing studies documenting the role of combination anti-PD1 + low dose anti-CTLA4 Ab in PD1 refractory disease, as well as establishing the role for, and FDA/EMA approval of, adjuvant anti-PD1 for stage IIB/C melanoma. More generally, Dr Luke has been a lead investigator for clinical trials of many novel immunotherapies in advanced solid tumors. He has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy.
Dr. Luke’s translational research laboratory focuses on biomedical and bioinformatic approaches to advance cancer immunotherapy. Dr. Luke is an At Large member of the Board of Directors for SITC and has held leadership roles in SMR, AACR & ASCO. Dr Luke is the PI or Project leader for multiple funding mechanisms including R01, UM1, P50 & multiple state or private grants.
Dr. Luke received his medical degree from Rosalind Franklin University of Medicine and Science/Chicago Medical School in North Chicago. He completed an internship and residency in internal medicine at Boston University Medical Center and fellowships in medicine and medical oncology at Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York.